Statement re Result of AGM and Board Appointment

14 JULY 2006

                             BILLAM PLC

                            RESULT OF AGM
                                 AND
                          BOARD APPOINTMENT

The Board of Billam plc (the  "Company") is pleased to announce  that
at its Annual General Meeting held  today at the offices of KBC  Peel
Hunt, 111  Old  Broad Street,  London,  EC2N 1PH,  all  ordinary  and
special resolutions were duly passed.

Following the AGM, Dimitri Dimitriou has been appointed as a director
of the Company, with immediate effect.

Dimitri Dimitriou,  MSc (aged  45) has  20 years'  experience in  the
pharmaceutical  and  biotech  industry  and  is  Chief  Executive  of
ImmuPharma PLC  which  is quoted  on  AIM. He  was  senior  director,
Worldwide  Business   Development  at   GlaxoSmithKline,  where   his
responsibilities included  corporate  deals with  pharmaceutical  and
biotech companies on a worldwide basis.   He is a founder and CEO  of
DyoDelta Biosciences, a company specialising in transactions  between
pharma and biotech  companies.   He moved  from a  senior big  pharma
position to the  biotech sector in  2001 as CEO  of the  London-based
drug discovery company  Xcellsyz.  His  other past positions  include
setting up and  heading the Business  Development function in  Europe
for Bristol-Myers Squibb, Product Manager in Marketing at Sandoz (now
Novartis), and 8 years in managerial positions in the  pharmaceutical
division of Procter & Gamble.

He received  his first  degree in  Biochemistry from  Kings  College,
University of London  prior to graduating  in Pathology &  Toxicology
from the  Royal Postgraduate  Medical  School (now  Imperial  College
Medical School) in London in 1984.

In addition to his appointment to the board of Billam plc, Dimitri
holds, or has held in the last 5 years, directorships and
partnerships as follows:


Current directorships    Past Directorships
or partnerships          or Partnerships
DyoDelta Biosciences Ltd Xcellsyz Ltd
W.O.C.P. Ltd             Polytherics Ltd
Medical Diagnosis Ltd
ImmuPharma PLC
ImmuPharma UK Limited
ImmuPharma (France) SA


There are no further details that are required to be disclosed  under
Schedule 2 paragraph (g) of the AIM Rules.

                              --ENDS--



ENQUIRIES:

Bishopsgate Communications
            020 7430 1600
Nick Rome
Fran Read

---END OF MESSAGE---